UK health tech company Medopad has announced its first acquisition as it accelerates its expansion into the United States.
Medopad has acquired Sherbit, a Silicon Valley artificial intelligence start-up that works with the largest US healthcare systems to improve chronic disease patient care.
Medopad鈥檚 technology connects patients with聽healthcare professionals, allowing them to analyse a patient’s data and detect life-threatening medical conditions.
It works with Royal Free London, Guy鈥檚 and St Thomas鈥�, Bart鈥檚, Chelsea & Westminster in the UK and is working on projects in counties including China, Germany and Singapore.
Named as a $1 billion聽HealthTech business in the making by KPMG, it says it is aiming to extend the lives of a billion people worldwide.
鈥淎t Medopad we want to create a world where people can live longer. We are working with some of the biggest companies in the world to improve the way doctors care for their patients by monitoring them at home and spotting any complications before they arise,鈥澛爏aid Medopad CEO and founder Dan Vahdat.
鈥淲e are expanding rapidly across the world and acquiring Sherbit is just the first step for us in the US.
鈥淪herbit has a strong track record of success working with some of the most prestigious healthcare organisations in the US, including the Mayo Clinic, Tufts Medical Center and Jefferson Health.
鈥淭hrough this acquisition, Medopad will provide its technology to support solutions across different disease areas from rare diseases to chronic conditions.鈥�
Sherbit CEO Alex Senemar said: 鈥淪herbit and Medopad have the same vision to help people be healthier and live longer.
鈥淲e鈥檙e excited to leverage Medopad鈥檚 technology, clinical, and predictive analytics capabilities to expand what鈥檚 possible for our customers.鈥�